ReviewClinical and experimental immunology2017
Adult vaccination against tetanus and diphtheria: the European perspective.
Review in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 84 citations in OpenAlex.
- Immunofitness in the elderly: The role of vaccination in promoting healthy aging.Human vaccines & immunotherapeutics · 2026Review
- Phase I Evaluation of Siltartoxatug, a First-in-Class Anti-Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations.Clinical pharmacology and therapeutics · 2026Article
- Article
- IgY technology (egg yolk antibodies) in respiratory medicine: applications and future prospects.Archives of microbiology · 2026Review
- Epidemiological investigation and public health response to a diphtheria outbreak in Jalalabad Union, Sylhet, December 2023.IJID regions · 2026Article
- Management and outcome of adult generalized tetanus patients in a tertiary hospital in Anhui, China: a retrospective study.Frontiers in public health · 2026Article
- Population waning trajectories of vaccine-induced tetanus immunity in Zhejiang, China.Frontiers in immunology · 2026Article
- Serological evaluation of immunity againstHuman vaccines & immunotherapeutics · 2025Article
- Tetanus: recognition and management.The Lancet. Infectious diseases · 2025Review
- Intrathecal monovalent fragments from two human monoclonal antibodies block tetanus neurotoxin in rodents.iScience · 2025Article
- Lessons learned from successful implementation of tetanus and diphtheria vaccination programs.Clinical microbiology reviews · 2025Review
- Localized tetanus bacillus infection following open metatarsal fracture in an adult: A case report.Medicine · 2025Article
- Local Tetanus Begins with a Neuromuscular Junction Paralysis around the Site of Tetanus Neurotoxin Release due to Cleavage of the Vesicle-Associated Membrane Protein.The American journal of pathology · 2024Article
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.Infectious diseases and therapy · 2024Article
- Review
- Seroepidemiology of Tetanus among Healthy People Aged 1-59 Years Old in Shaanxi Province, China.Vaccines · 2022Article
- Experts' Opinion for Improving Pertussis Vaccination Rates in Adolescents and Adults: A Call to Action.International journal of environmental research and public health · 2022Review
- Tdap Booster Vaccination for Adults: Real-World Adherence to Current Recommendations in Italy and Evaluation of Two Alternative Strategies.International journal of environmental research and public health · 2022Article
- Vaccination coverage of patients with type 2 diabetes mellitus: Challenging issues from an outpatient secondary care setting in Greece.Frontiers in public health · 2022Article
- Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond.Immunity & ageing : I & A · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Besides immunizations against influenza, Streptococcus pneumoniae and herpes zoster, which are recommended specifically for elderly people, regular booster vaccinations against tetanus, diphtheria and in some cases pertussis and polio are recommended in many European countries for adults, including elderly people. Vaccination recommendations for adults differ greatly between individual countries and coverage data is scarce. Tetanus-specific antibody concentrations are generally higher than diphtheria-specific antibodies, and a substantial proportion of adults, and particularly of elderly people, do not have protective antibody concentrations against diphtheria. Antibody levels increase upon booster vaccination in all age groups, but diphtheria-specific antibody concentrations remain below protective levels in some older individuals, even immediately after vaccination and long-term protection is frequently not achieved. Future vaccination strategies should therefore include regular and well-documented booster shots, e.g. against tetanus and diphtheria, throughout life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.